INT29651

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 1984
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 11
Total Number 12
Disease Relevance 9.95
Pain Relevance 2.79

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
nucleus ambiguus 1
body 1
Pah (Rattus norvegicus)
Pain Link Frequency Relevance Heat
MU agonist 6 100.00 Very High Very High Very High
antagonist 78 99.82 Very High Very High Very High
Enkephalin 14 99.56 Very High Very High Very High
fluoxetine 15 99.44 Very High Very High Very High
opioid receptor 1 98.68 Very High Very High Very High
agonist 8 97.36 Very High Very High Very High
potassium channel 2 89.04 High High
imagery 1 88.16 High High
sSRI 3 85.60 High High
Serotonin 16 82.76 Quite High
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 1162 100.00 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 46 100.00 Very High Very High Very High
Thrombosis 23 99.76 Very High Very High Very High
Increased Venous Pressure Under Development 74 99.16 Very High Very High Very High
Coronary Heart Disease 27 97.24 Very High Very High Very High
Systemic Sclerosis 83 95.60 Very High Very High Very High
Infection 34 95.28 Very High Very High Very High
Hypoxia 72 92.92 High High
Disease 115 90.44 High High
Primary Pulmonary Hypertension 17 88.92 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, little is known about pathophysiological features after reversal or attenuation of PAH; moreover, the long-term therapeutic effects of SERT inhibitors on PAH remain undetermined.
Regulation (effects) of PAH associated with pulmonary hypertension
1) Confidence 0.37 Published 2009 Journal Clin. Exp. Pharmacol. Physiol. Section Abstract Doc Link 19473340 Disease Relevance 0.88 Pain Relevance 0.33
The 5-HT receptor antagonists did not affect PAH.
Neg (not) Regulation (affect) of PAH associated with pulmonary hypertension and antagonist
2) Confidence 0.29 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 1.13 Pain Relevance 0.59
The role of the characteristic plexiform lesions in the pathogenesis and natural history of PAH is unclear.
Regulation (role) of PAH associated with pulmonary hypertension
3) Confidence 0.28 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350123 Disease Relevance 1.40 Pain Relevance 0.03
None of the placebo-controlled trials of bosentan in PAH were powered to show survival benefit.
Regulation (controlled) of PAH associated with pulmonary hypertension
4) Confidence 0.24 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350123 Disease Relevance 0.39 Pain Relevance 0
Recommendations for role of bosentan monotherapy in PAH
Regulation (role) of PAH associated with pulmonary hypertension
5) Confidence 0.24 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350123 Disease Relevance 0.93 Pain Relevance 0
Effect of bosentan on survival in idiopathic PAH
Regulation (Effect) of PAH associated with pulmonary hypertension
6) Confidence 0.24 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350123 Disease Relevance 0.37 Pain Relevance 0
subunit is post-transcriptionally regulated by prolyl and asparaginyl hydroxylase (PAH) activity for the HIF-1?
Regulation (regulated) of PAH
7) Confidence 0.23 Published 2007 Journal The Open Biochemistry Journal Section Body Doc Link PMC2570544 Disease Relevance 0.41 Pain Relevance 0.04
There are a number of different pathways involved in the control of PVR, many of which are therapeutic targets in the management of PAH, and are therefore essential to an understanding of the management of this condition (Table 4).
Regulation (targets) of PAH associated with pulmonary hypertension
8) Confidence 0.19 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2697585 Disease Relevance 0.80 Pain Relevance 0.14
In a study on the effects of bosentan on human immunodeficiency virus associated PAH, Sitbon and colleagues (2004) described the results of bosentan therapy given for 16-weeks in 16 patients.
Regulation (effects) of PAH associated with pulmonary hypertension and acquired immune deficiency syndrome or hiv infection
9) Confidence 0.15 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350123 Disease Relevance 1.90 Pain Relevance 0
In addition, the role of iloprost for the control of acute PAH during surgery will be discussed.
Regulation (control) of PAH associated with pulmonary hypertension
10) Confidence 0.04 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2686263 Disease Relevance 1.60 Pain Relevance 0.04
The respiratory and cardiovascular effects of the highly selective mu opioid agonist, D-Ala2, MePhe4, Gly- ol5 enkephalin ( DAGO ) and the relatively selective delta agonist, D-Leu5 enkephalin (DADL) were compared following injection (0.1 microliter) into the nucleus ambiguus (NA) of spontaneously-breathing and artificially-respired, pentobarbital-anesthetized rats.
Regulation (effects) of MePhe4 in nucleus ambiguus associated with mu agonist, agonist and enkephalin
11) Confidence 0.01 Published 1984 Journal Neuropharmacology Section Abstract Doc Link 6328352 Disease Relevance 0.07 Pain Relevance 0.63
The authors examined the effect (i.c.v.) of the selective mu, delta and kappa opioid agonists, [D-Ala2, MePhe4, Gly5-ol] enkephalin (DAGO), [D-Pen2, D-Pen5] enkephalin and U50488H, respectively, on the body temperature of restrained and unrestrained rats.
Spec (examined) Regulation (effect) of MePhe4 in body associated with mu agonist and enkephalin
12) Confidence 0.01 Published 1988 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 2839673 Disease Relevance 0.08 Pain Relevance 0.98

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox